Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$51.99
$51.95
$14.95
$52.00
$3.71B1.221.68 million shs113 shs
Insmed, Inc. stock logo
INSM
Insmed
$105.90
+0.5%
$76.19
$60.40
$106.58
$20.00B0.82.17 million shs4.43 million shs
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$58.70
$58.82
$27.30
$64.41
$4.12B0.772.76 million shsN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$26.78
+1.2%
$26.23
$23.14
$30.93
$3.64B0.461.46 million shs925,659 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00%0.00%0.00%0.00%0.00%
Insmed, Inc. stock logo
INSM
Insmed
+0.46%+5.60%+56.82%+38.30%+54.76%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00%0.00%0.00%0.00%0.00%
Perrigo Company plc stock logo
PRGO
Perrigo
+1.31%+1.91%+0.97%-2.15%+2.51%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
3.4788 of 5 stars
2.51.00.04.33.31.70.6
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
4.6454 of 5 stars
2.13.04.23.52.71.72.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.00
N/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$106.800.85% Upside
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
0.00
N/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0023.24% Upside

Current Analyst Ratings Breakdown

Latest INSM, MRTX, PRGO, and CCXI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $109.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $120.00
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy
6/10/2025
Insmed, Inc. stock logo
INSM
Insmed
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$100.00 ➝ $115.00
(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
$32.22M115.14N/AN/A$4.09 per share12.71
Insmed, Inc. stock logo
INSM
Insmed
$363.71M55.24N/AN/A$1.60 per share66.19
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
$12.44M331.01N/AN/A$17.31 per share3.39
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.84$5.11 per share5.24$31.66 per share0.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
-$131.76M-$1.89N/AN/AN/A-357.01%-48.52%-30.59%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
-$740.87M-$12.22N/AN/AN/A-1,900.65%-82.15%-67.82%N/A
Perrigo Company plc stock logo
PRGO
Perrigo
-$171.80M-$1.31N/A8.75N/A-4.16%8.93%3.87%8/1/2025 (Estimated)

Latest INSM, MRTX, PRGO, and CCXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.33%N/AN/A 23 Years

Latest INSM, MRTX, PRGO, and CCXI Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
0.02
4.54
4.47
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
7.54
7.40
Perrigo Company plc stock logo
PRGO
Perrigo
0.82
2.36
1.28

Institutional Ownership

CompanyInstitutional Ownership
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
81.09%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
N/A
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%

Insider Ownership

CompanyInsider Ownership
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
8.30%
Insmed, Inc. stock logo
INSM
Insmed
3.00%
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
3.26%
Perrigo Company plc stock logo
PRGO
Perrigo
0.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ChemoCentryx, Inc. stock logo
CCXI
ChemoCentryx
17871.36 million65.43 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
Mirati Therapeutics, Inc. stock logo
MRTX
Mirati Therapeutics
58770.15 million67.86 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,379137.48 million136.93 millionOptionable

Recent News About These Companies

Should Value Investors Buy Perrigo (PRGO) Stock?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
ChemoCentryx stock logo

ChemoCentryx NASDAQ:CCXI

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Insmed stock logo

Insmed NASDAQ:INSM

$105.90 +0.48 (+0.46%)
Closing price 06/24/2025 04:00 PM Eastern
Extended Trading
$105.08 -0.83 (-0.78%)
As of 06/24/2025 06:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Mirati Therapeutics stock logo

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.78 +0.33 (+1.23%)
Closing price 06/24/2025 03:59 PM Eastern
Extended Trading
$26.76 -0.02 (-0.08%)
As of 06/24/2025 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.